Alterity Therapeutics Limited (ATHE) Daily Stock Prediction

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian’s disease and other neurodegenerative diseases in Australia. The company’s lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

12

Address:

Alterity Therapeutics Limited 460 Bourke Street Level 3 Melbourne VIC 3000 Australia

Website:

Home

Phone:

61 3 9349 4906